ArticleIn vivo (Athens, Greece)

Cardiovascular Adverse Events Associated With Carfilzomib, Bortezomib, and Ixazomib: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database With Anticancer Agents as the Reference Group.

Masaki Fujiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.